A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes

NCT04353817 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

121

Enrollment

INDUSTRY

Sponsor class

Conditions

Cystic Fibrosis

Interventions

DRUG: ELX/TEZ/IVA
DRUG: IVA
OTHER: Placebo (matched to ELX/TEZ/IVA)
OTHER: Placebo (matched to IVA)

Sponsor

Vertex Pharmaceuticals Incorporated